OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Identification and validation of PCSK9 as a prognostic and immune-related influencing factor in tumorigenesis: a pan-cancer analysis
Chao Sun, Guoji Zhu, Conghuan Shen, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 8
Chao Sun, Guoji Zhu, Conghuan Shen, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 8
Showing 8 citing articles:
Drug development advances in human genetics‐based targets
X. Zhang, Wenjun Yu, Yan Li, et al.
MedComm (2024) Vol. 5, Iss. 2
Open Access | Times Cited: 6
X. Zhang, Wenjun Yu, Yan Li, et al.
MedComm (2024) Vol. 5, Iss. 2
Open Access | Times Cited: 6
Unraveling the link between cholesterol and immune system in cancer: from biological mechanistic insights to clinical evidence. A narrative review
Federica Pecci, Valeria Cognigni, Giulia Claire Giudice, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104654-104654
Closed Access
Federica Pecci, Valeria Cognigni, Giulia Claire Giudice, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104654-104654
Closed Access
Prognostic implications of PCSK9 expression in HER2-positive breast cancer
Zongwen Wu, D. Wu, Chengsheng Huang, et al.
ONCOLOGIE (2025)
Closed Access
Zongwen Wu, D. Wu, Chengsheng Huang, et al.
ONCOLOGIE (2025)
Closed Access
Effects of PCSK9 inhibitors on cancer, diabetes, and cardiovascular diseases
Mojgan Nejabat, Farzin Hadizadeh, Wael Almahmeed, et al.
Drug Discovery Today (2025), pp. 104316-104316
Closed Access
Mojgan Nejabat, Farzin Hadizadeh, Wael Almahmeed, et al.
Drug Discovery Today (2025), pp. 104316-104316
Closed Access
Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis
Kavita A. Iyer, Julian Ivanov, Rumiana Tenchov, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 11, pp. 8519-8544
Open Access | Times Cited: 2
Kavita A. Iyer, Julian Ivanov, Rumiana Tenchov, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 11, pp. 8519-8544
Open Access | Times Cited: 2
Inhibition of PCSK9 enhances the anti-hepatocellular carcinoma effects of TCR-T cells and anti-PD-1 immunotherapy
Weikang Xu, Minli Hu, Xinyu Lu, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 10, pp. 3942-3955
Open Access | Times Cited: 2
Weikang Xu, Minli Hu, Xinyu Lu, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 10, pp. 3942-3955
Open Access | Times Cited: 2
Emerging Targets and Therapeutics in Immuno-Oncology Landscape: Insights from Natural Language Processing Analysis
Kavita A. Iyer, Julian Ivanov, Rumiana Tenchov, et al.
(2023)
Open Access | Times Cited: 2
Kavita A. Iyer, Julian Ivanov, Rumiana Tenchov, et al.
(2023)
Open Access | Times Cited: 2
Prognostic Value of PCSK9 Levels in Premenopausal Women at Risk of Breast Cancer—Evidence from a 17-Year Follow-Up Study
Massimiliano Ruscica, Chiara Macchi, Sara Gandini, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1411-1411
Open Access
Massimiliano Ruscica, Chiara Macchi, Sara Gandini, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1411-1411
Open Access
